Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Factorial, the start-up, said the listing would provide money that would help it bring new solid-state batteries to market as soon as 2027. By Jack Ewing Factorial Energy, which is developing advanced ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Kara Alaimo is an associate professor of communication at Fairleigh Dickinson University. Her book “Over the Influence: Why Social Media Is Toxic for Women and Girls — And How We Can Take It Back” was ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Follow 24/7 Wall St. on Google By Joey Frenette Published ...

Robot and human fingers reach out to the other, symbolizing the promise of our future. Artificial intelligence has the power to transform our lives. It needs humans to step up to harness this power.

After two and a half years we have enough data to form a clearer picture about who is using AI, what they are using it for, what they think about it, and what it means for learning. What do students ...

Associate Professor and Associate Director of the Centre for Change and Complexity in Learning (C3L), Education Futures, University of South Australia Since ChatGPT appeared almost three years ago, ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...